Notice of Intent to Sole Source- Cost-Per-Test - Reagents for BCR-ABL Tests

This Special Notice from the Department of the Army Medical Command seeks to award a sole-source contract to Asuragen, Inc. for the procurement of BCR-ABL reagents for leukemia testing at Brooke Army Medical Center. The justification document attached to the notice seeks approval for awarding a contract to Asuragen for a base period from 1 October 2022 to 30 September 2023, with a total value of $1,037,640 including four one-year option periods.

The purpose of the sole-source award is to procure FDA-approved clinical reagents that are compatible with the government-owned Applied Biosystems 7500 Fast Dx Real-Time PCR instruments used for leukemia testing at the medical center. Market research found that Asuragen is the only supplier that can meet this requirement. The Department of the Army Medical Command intends to award the contract before 30 September 2022, subject to availability of FY23 Defense Health Program funds. No other contractors were found to be eligible based on the compatibility requirement and the need to maintain operations of specialized medical equipment.